Atossa Therapeutics financials
$1.99+1.53%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$37.1M | -$29.3M | -$31.4M | -$27.7M | -$20.5M | -$14.6M | -$17.3M | -$11.4M | -$7.6M | -$8.0M |
| Net income | -$34.8M | -$25.5M | -$30.1M | -$27.0M | -$20.6M | -$22.3M | -$17.2M | -$22.9M | -$10.7M | -$6.4M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-4.04 | $-3.04 | $-3.60 | $-3.15 | $-2.70 | $-29.55 | $-30.45 | $-82.50 | $-164.55 | $-388.80 |
| EBITDA | -$37.1M | -$27.6M | -$31.4M | -$27.7M | -$20.5M | -$14.6M | -$17.2M | -$11.4M | -$7.1M | -$6.9M |
| Operating cash flow | -$29.8M | -$21.0M | -$20.9M | -$20.8M | -$16.5M | -$11.6M | -$9.1M | -$9.0M | -$6.6M | -$5.4M |
| Free cash flow | -$29.8M | -$21.0M | -$21.0M | -$20.8M | -$16.5M | -$11.6M | -$9.1M | -$9.1M | -$6.6M | -$5.4M |
| Diluted shares | 8.6M | 8.4M | 8.4M | 8.4M | 7.8M | 0.8M | 0.6M | 0.3M | 0.1M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $41.3M | $71.1M | $88.5M | $110.9M | $136.4M | $39.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $47.6M | $76.4M | $96.3M | $123.5M | $141.3M | $42.8M |
| Total liabilities | $8.3M | $5.0M | $5.2M | $5.6M | $3.1M | $15.7M |
| Shareholders' equity | $39.4M | $71.5M | $91.0M | $118.0M | $138.1M | $27.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology